IP Library Granted Patent US 7,109,331
Granted Patent B2
US 7,109,331 · App. 10/363,424 · Granted Sep 19, 2006

5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors

Assignees: Industrial Research Limited; Albert Einstein College of Medicine of Yeshiva University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,109,331
App. No.
10/363,424
Granted
Sep 19, 2006
Kind
B2
Abstract

The present invention provides a compound of the formula (I): wherein A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH 2 , NHR 1 , NR 1 R 2 and SR 3 , where R 1 , R 2 and R 3 are each optionally substituted alkyl, aralkyl or aryl groups; B is selected from OH, NH 2 , NHR 4 , H and halogen, where R 4 is an optionally substituted alkyl, aralkyl or aryl group; D is selected from OH, NH 2 , NHR 5 , H, halogen and SCH 3 , where R 5 is an optionally substituted alkyl, aralkyl or aryl group; X and Y are independendy selected from H, OH and halogen, with the proviso that when one of X and Y is hydroxy or halogen, the other is hydrogen; Z is OH, or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ and OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group; and W is OH or H, with the proviso that when W is OH, then A is CR where R is as defined above; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof. The invention also provides pharmaceutical compositions comprising compounds of formula (I), methods of preparing compounds of formula (I), and methods of treatment using compounds of formula (I).

Claims (38)

1. A compound of the formula:

wherein:

A is CH or CR, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH 2 , NHR 1 , NR 1 R 2 and SR 3 , where R 1 , R 2 and R 3 are each optionally substituted alkyl, aralkyl or aryl groups;

B is OH;

D is selected from OH, NH 2 , NHR 5 , H, halogen and SCH 3 , where R 5 is an optionally substituted alkyl, aralkyl or aryl group;

X and Y are independently selected from H, OH and halogen, with the proviso that when one of X and Y is hydroxy or halogen, the other is hydrogen;

Z is OH, or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ and OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group; and

W is OH or H, with the proviso that when W is OH, then A is CR where R is as defined above;

or a tautomer thereof; or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1 , wherein D is NHR 5 , and R 5 is C 1 –C 4 alkyl.

3. A compound as claimed in claim 1 wherein when one or more halogens are present, they are chosen from chlorine or fluorine.

4. A compound as claimed in claim 1 wherein when Z is SQ or OQ, Q is C 1 –C 5 alkyl or phenyl.

5. A compound as claimed in claim 1 wherein either D is H.

6. A compound as claimed in claim 1 wherein D is H, OH or NH 2 , X is OH or H and Y is H.

7. A compound as claimed in claim 1 wherein Z is OH, H or methylthio.

8. A compound as claimed in claim 1 wherein W is OH, Y is H, X is OH, and A is CR where R is methyl or halogen.

9. A compound as claimed in claim 1 wherein W is H, Y is H, X is OH and A is CH.

10. A compound as claimed in claim 1 selected from

(1S)-1-(9-deaza-8-fluorohypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;

(1S)-1-(9-deaza-8-methylhypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol; or

( 1 S)-1-(9-deazahypoxanthin-9-yl)-1,3,4trideoxy-1,4-imino-D-ribitol;

or a tautomer thereof; or a pharmaceutically acceptable salt thereof.

11. A composition comprising a compound of the formula (I) as claimed in claim 1 , and a carrier or diluent.

12. A method for preparing a compound of the formula (I) as defined in claim 1 , wherein A is CR and R is as defined in claim 1 , the method comprising reacting a compound of formula (II)

wherein R 9 is an alkoxycarbonyl or aralkyloxycarbonyl group, Z′ is a hydrogen or halogen atom, a group of formula SQ or OQ, or a trialkylsilyloxy, alkyldiarylsilyloxy or optionally substituted triarylmethoxy group and Q is an optionally substituted alkyl, aralkyl or aryl group, and R 6 is an N-protecting group, B′ and D′ are independently selected from H, OR 7 and N(R 8 ) 2 , and R 7 and R 8 are O- and N-protecting groups respectively;

(i) with a strong base capable of deprotonation at C-8 of the 9-deazapurine moiety; then

(ii) with an electrophile selected from the group consisting of an alkyl halide, an aldehyde, a formylating agent and N-fluorosulfomidobenzene; and

(iii) O- and N-deprotecting the product by acid-, alkali- or fluoride ion-catalyzed hydrolysis or alcoholysis or catalytic hydrogenolysis as required for the O- and N-protecting groups in use.

13. A method as claimed in claim 12 wherein the strong base comprises butyllithium.

14. A method for preparing a compound of the formula (I) as defined in claim 1 , wherein W is H, the method comprising reacting a compound of formula (III)

wherein R 9 is an alkoxycarbonyl or aralkyloxycarbonyl group, Z′ is a hydrogen or halogen atom, a group of formula SQ or OQ, or a trialkylsilyloxy, alkyldiarylsilyloxy or optionally substituted triarylmethoxy group and Q is an optionally substituted alkyl, aralkyl or aryl group, and R 6 is an N-protecting group, B′ and D′ are independently selected from H, OR 7 and N(R 8 ) 2 , R 7 and R 8 are O- and N-protecting groups, respectively, and R 10 is an O-protecting group;

(i) with a thiocarbonylating agent; then

(ii) with a radical reducing agent; and

(iii) O- and N-deprotecting the product by acid-, alkali- or fluoride ion-catalyzed hydrolysis or alcoholysis or catalytic hydrogenolysis as required for the O- and N-protecting groups in use.

15. A method as claimed in claim 14 wherein the thiocarbonylating agent is thiocarbonyl diimidazole.

16. A method as claimed in claim 14 wherein the radical reducing agent comprises tributyltin hydride.

17. The method of claim 12 , wherein the electrophile is N-fluorosulfomidobenzene.

18. The method of claim 12 , wherein the electrophile is methyl iodide, acetaldehyde or dimethylformamide.

Assignments (6)
GOVERNMENT INTEREST AGREEMENT Recorded Jul 21, 2015
From: ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 036140/0500 →
GOVERNMENT INTEREST AGREEMENT Recorded Jul 21, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERISTY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 036143/0652 →
GOVERNMENT INTEREST AGREEMENT Recorded Jul 21, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 036144/0563 →
CONFIRMATORY LICENSE Recorded Jun 22, 2012
From: YESHIVA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028429/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2003
From: SCHRAMM, VERN L.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
Reel/Frame 014563/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2003
From: FURNEAUX, RICHARD HUBERT; TYLER, PETER CHARLES
To: INDUSTRIAL RESEARCH LIMITED, A NEW ZEALAND COMPANY
Reel/Frame 014563/0066 →
Priority Claims (1)
NZ 506613 · Aug 29, 2000 · national
Continuity (1)
Related Publication 20040053944A1 · Mar 18, 2004